GRIN Therapeutics Receives FDA Breakthrough Therapy Designation for Radiprodil
Press Releases
GRIN Therapeutics Inc.  
February 25, 2025

GRIN Therapeutics Receives FDA Breakthrough Therapy Designation for Radiprodil

Designation for treatment of seizures associated with GRIN-related neurodevelopmental disorder in patients with gain-of-function mutations recognizes radiprodil's potential to demonstrate substantial improvement over available symptom-based therapyCompany preparing to initiate Phase

avatar profile Olean Times Herald

Olean Times Herald


Local & Social